Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab

Men, Mauranda; Tsui, Edmund

doi:10.1016/j.ajoc.2022.101631

Cited by 6 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In regards to the safety profile, the IMpassion130 trial reported alopecia in 56.4% of patients, nausea in 46.0% of patients, and cough in 24.8% of patients, but no ocular adverse events similar to the present case were reported. On the other hand, several reports of ophthalmologic side effects, such as CME, caused by the administration and completion of treatment with immune checkpoint inhibitors have been reported as immune-related adverse events [24, 25]. This suggests that regular follow-up is necessary even after completion of treatment with immune checkpoint inhibitors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer

Yamane,

Itagaki,

Kajitani

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Cystoid macular edema (CME) is a rare side effect associated with chemotherapy. Although the development of CME has been reported to occur following treatment with taxane drugs, such as nanoparticle albumin-bound paclitaxel (Nab-PTX), the occurrence of CME with treatment with atezolizumab has not yet been reported. Here, we report the case of a 49-year-old woman who developed CME 19 months into chemotherapy with Nab-PTX and atezolizumab. Improvement was not achieved with steroid injections into the Tenon’s sac, and Nab-PTX and atezolizumab treatments were ceased. One month later, there was subjective improvement in her symptoms. Although many reports have indicated that cessation of chemotherapy has successfully improved CME, a specific treatment for CME has not yet been established. Clinicians should be aware of the ophthalmologic side effects and offer immediate treatment if symptoms develop.

show abstract

Section: Discussionmentioning

confidence: 99%

“…immune-related adverse events [24,25]. This suggests that regular follow-up is necessary even after completion of treatment with immune checkpoint inhibitors.…”

Section: Case Reports In Oncologymentioning

confidence: 99%

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer

Yamane,

Itagaki,

Kajitani

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…Ocular Epstein-Barr virus (EBV), toxoplasmosis, herpes simplex, syphilis, Lyme disease, and tuberculosis must be ruled out as infectious causes. Serologies, fluorescent treponemal antibody absorption test (FTA-ABS), Treponema pallidum particle agglutination (TP-PA), rapid plasma regain (RPR), and/or QuantiFERON-TB tests can thereby be obtained [123,172].…”

Section: Laboratory Investigationsmentioning

confidence: 99%

“…Fluorescein or indocyanine green angiographies are helpful to visualize vascular changes in posterior uveitis, birdshot chorioretinopathy, and VKH-like uveitis [66]. They reveal vascular leakage evidence of vasculitis, neovascularization, retinal artery or vein occlusion, and the like [172,183].…”

Section: Imaging Investigationsmentioning

confidence: 99%

Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review

Zhang,

Houadj,

et al. 2024

Diagnostics

View full text Add to dashboard Cite

This review aims to provide an understanding of the diagnostic and therapeutic challenges of uveitis associated with immune checkpoint inhibitors (ICI). In the wake of these molecules being increasingly employed as a treatment against different cancers, cases of uveitis post-ICI therapy have also been increasingly reported in the literature, warranting an extensive exploration of the clinical presentations, risk factors, and pathophysiological mechanisms of ICI-induced uveitis. This review further provides an understanding of the association between ICIs and uveitis, and assesses the efficacy of current diagnostic tools, underscoring the need for advanced techniques to enable early detection and accurate assessment. Further, it investigates the therapeutic strategies for ICI-related uveitis, weighing the benefits and limitations of existing treatment regimens, and discussing current challenges and emerging therapies in the context of their potential efficacy and side effects. Through an overview of the short-term and long-term outcomes, this article suggests recommendations and emphasizes the importance of multidisciplinary collaboration between ophthalmologists and oncologists. Finally, the review highlights promising avenues for future research and development in the field, potentially informing transformative approaches in the ocular assessment of patients under immunotherapy and the management of uveitis following ICI therapy.

show abstract

Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis

Wu,

Sun,

Wang

2024

Invest New Drugs

View full text Add to dashboard Cite

Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab

Cited by 6 publications

References 15 publications

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer

Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review

Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis

Contact Info

Product

Resources

About